Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma

Annals of Surgery

Volumn 268, Issue 5, 2018, Pages 868-875

  Pinna, Antonio Daniele ^a   Yang, Tian ^b   Mazzaferro, Vincenzo ^c   De Carlis, Luciano ^d   Zhou, Jian ^e   Roayaie, Sasan ^f   Shen, Feng ^b   Sposito, Carlo ^b   Cescon, Matteo ^a   Di Sandro, Stefano ^d   Yi Feng, He ^e   Johnson, Philip ^g   Cucchetti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e FUDAN UNIVERSITY   (China)

^f White Plains Hospital Center   (United States)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cirrhosis; Disease free survival; General population; Hepatic resection; Hepatocellular carcinoma; Liver transplant; Overall survival; Partial hepatectomy; Statistical cure; Survival benefit; Tumor recurrence; Waiting list removal

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR RECURRENCE; AGED; CHINA; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; REOPERATION; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHINA; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REOPERATION; TREATMENT OUTCOME;

EID: 85054757417     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002889     Document Type: Article

References (32)

1. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.
2. Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017; 67:585–602.
3. Cucchetti A, Vitale A, Del Gaudio M, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant. 2010;10:619–627.
4. Proneth A, Zeman F, Schlitt HJ, et al. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and meta-analysis. Ann Surg Oncol. 2014; 21:3096–3107.
5. Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant. 2008;8:1177–1185.
6. Poon RTP, Fan ST, Lo CM, et al. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg. 2007;245:51–58.
7. Koniaris LG, Levi DM, Pedroso FE, et al. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg. 2011;254:527–537.
8. Vitale A, Cucchetti A, Qiao GL, et al. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on ‘‘number of patients needed to transplant’’ as measure of transplant benefit. J Hepatol. 2014;60:1165–1171.
9. Cillo U, Vitale A, Polacco M, et al. Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology. 2017;65:1741–1748.
10. Othus M, Barlogie B, Leblanc ML, et al. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18:3731–3736.
11. Lambert PC, Thompson JR, Weston CL, et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007;8:576–594.
12. Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death following liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154:128–139.
13. Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62:440–451.
14. Cucchetti A, Cescon M, Golfieri R, et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol. 2016;64:79–86.
15. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg. 2013;257:929–937.
16. Cucchetti A, Zanello M, Cescon M, et al. Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of Bologna experience over 10 years. Ann Surg Oncol. 2011;18:1630–1637.
17. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.
18. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
19. Yao FY. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.
20. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994.
21. Fan J, Yang G-S, Fu Z-R, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol. 2009;135:1403–1412.
22. Lambert PC. Modeling of the cure fraction in survival studies. Stata J. 2007;7:351–375.
23. Tsodikov AD, Ibrahim JG, Yakovlev AY. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003;98:1063–1078.
24. World Health Organization. Global Health Observatory (GHO) Data on Life Expectancy. Available at: http://www.who.int/gho/mortality_burden_disease/life_tables. Accessed September 15, 2017.
25. Statistical Methodology and Applications Branch, Data Modeling Branch, National Cancer Institute. Cansurv, Version 1.3. Available at: https://surveillance.cancer.gov/cansurv/. Accessed September 15, 2017.
26. Kudo M. Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. Liver Cancer. 2015;4:85–95.
27. Cucchetti A, Ferrero A, Cescon M, et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015; 22:1908–1914.
28. Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121:3998–4006.
29. Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–806.
30. Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. J Surg Oncol. 2017;116:288–297.
31. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146:683–689.
32. Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for ‘‘very early’’ intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64:1178–1188.